ly 300164 has been researched along with fg 9041 in 1 studies
| Studies (ly 300164) | Trials (ly 300164) | Recent Studies (post-2010) (ly 300164) | Studies (fg 9041) | Trials (fg 9041) | Recent Studies (post-2010) (fg 9041) |
|---|---|---|---|---|---|
| 73 | 7 | 12 | 812 | 0 | 122 |
| Protein | Taxonomy | ly 300164 (IC50) | fg 9041 (IC50) |
|---|---|---|---|
| Chain A, GLUTAMATE RECEPTOR SUBUNIT 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| Chain A, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| Chain B, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.998 | |
| fatty acid synthase | Homo sapiens (human) | 7.755 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor 1 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 2 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 3 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor 4 | Homo sapiens (human) | 1.51 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.1 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carcache, D; Kalkman, HO; Koller, M; Mattes, H | 1 |
1 other study(ies) available for ly 300164 and fg 9041
| Article | Year |
|---|---|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA | 2010 |